Somnath Mukherjee to Antibodies, Monoclonal
This is a "connection" page, showing publications Somnath Mukherjee has written about Antibodies, Monoclonal.
Connection Strength
0.188
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020 12; 21(12):1574-1588.
Score: 0.105
-
Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody. Sci Rep. 2017 04 03; 7(1):556.
Score: 0.083